Soleno Therapeutics, Inc.
SLNO
$33.39
-$0.37-1.08%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 38.95% | 102.16% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 38.95% | 102.16% | |||
| Cost of Revenue | -24.36% | 63.94% | |||
| Gross Profit | 40.06% | 102.99% | |||
| SG&A Expenses | 21.11% | 19.53% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 18.48% | 13.70% | |||
| Operating Income | 77.96% | 518.86% | |||
| Income Before Tax | 66.68% | 652.53% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 66.68% | 652.53% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 66.68% | 652.53% | |||
| EBIT | 77.96% | 518.86% | |||
| EBITDA | 76.31% | 571.78% | |||
| EPS Basic | 65.56% | 622.83% | |||
| Normalized Basic EPS | 66.49% | 798.21% | |||
| EPS Diluted | 68.15% | 603.75% | |||
| Normalized Diluted EPS | 67.85% | 777.85% | |||
| Average Basic Shares Outstanding | -0.29% | 5.64% | |||
| Average Diluted Shares Outstanding | -1.08% | 8.79% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||